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evident on the Satisfaction domain and the Psychological
Reward domain.
PSM3
CONFIRMATORY VALIDATION OF THE BRIEF
QUESTIONNAIRE OF SMOKING URGES
Cappelleri JC1, Bushmakin AG1, Baker CL2, Merikle E3, Olufade AO2,
Gilbert DG4
1Pﬁzer Global Research and Development, Groton, CT, USA;
2Pﬁzer Global Pharmaceuticals, New York, NY, USA; 3Pﬁzer Canada,
Montreal, QC, Canada; 4Southern Illinois University, Carbondale, IL,
USA
OBJECTIVES: The 10-item version of the 32-item Questionnaire
of Smoking Urges (the QSU-brief) provides a multidimensional
measure of craving to smoke. Previous research from a factor
analysis of the QSU-brief supported a two-factor structure with
Factor 1 measuring “a strong desire and intention to smoke 
with smoking perceived as rewarding” and Factor 2 measuring
“demonstrating anticipation of relief from negative affect and an
urgent desire to smoke”. We conducted an independent investi-
gation of the QSU-brief to assess the validity and reliability of
the proposed two-factor structure. METHODS: Data came from
a seven-week Phase II clinical trial (n = 626) of varenicline devel-
oped for smoking cessation. The two pre-speciﬁed domains from
previous research were Factor 1 (5 items) and Factor 2 (3 items).
Factor analyses and internal consistency reliability analyses
(Cronbach’s alpha) were conducted during occasions when
varying levels of craving intensity might be expected (baseline,
Week 2, and Week 4). RESULTS: The hypothesized multidi-
mensional framework of the QSU-brief was supported by con-
ﬁrmatory factor analysis at each of the three occasions (baseline,
Week 2, Week 4). Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) exceeded 0.90 (CFI = 0.97, 0.95, 0.96; NNFI
= 0.96, 0.93, 0.95). Values of Cronbach’s alpha exceeded 0.75
on Factor 1 (0.90, 0.89, 0.90) and Factor 2 (0.76, 0.78, 0.85),
as well as on the Total Score of 10 items (0.92, 0.93, 0.93).
CONCLUSION: The validity and reliability of the postulated
two dimensional structure of self-reported craving as measured
by the QSU-brief is conﬁrmed.
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OBJECTIVES: To assess the cost-effectiveness of 18-month
treatment with clopidogrel versus aspirin in high-risk patients
with a recent history of Ischemic Stroke (IS) or Transient
Ischemic Attack (TIA) in four European countries: Belgium,
France, Switzerland, and UK. METHODS: We developed a
Markov model based on patients with IS or TIA in the previous
90 days (median 15 days) who were treated with clopidogrel in
the MATCH trial and followed prospectively for the occurrence
of recurrent IS or TIA, myocardial infarction (MI), other car-
diovascular death, life threatening bleeding, or major bleeding.
The event rates for IS and TIA patients treated with aspirin were
derived from a Cochrane review comparing clopidogrel and
aspirin by using a relative risk increase (RRI) of 1.11 for serious
vascular events (all strokes, MI, cardiovascular deaths). For
major bleedings with aspirin vs. clopidogrel, we used a RRI of
1.12 (CAPRIE trial). Death rates for other causes were country
speciﬁc and adjusted for this population. Lifetime perspective
was chosen and discount rates were applied according to the
local guidelines. RESULTS: Eighteen-month treatment with
clopidogrel compared to aspirin was associated with a gain in
quality adjusted life years (QALY) ranging from 31 years/1000
patients in the UK to 36 years/1000 patients in Belgium. 
The incremental cost per patient varied from 487€ in UK to 
724€ in Belgium and the cost per QALY was 20,111€ in 
Belgium, 18,882€ in France, 15,620€ in Switzerland, and
15,713€ in UK. Sensitivity analyses showed that all results were
robust under various assumptions. CONCLUSION: Consistent
results are found across the four countries with incremental cost-
effectiveness ratio below the acceptable thresholds, demonstrat-
ing that clopidogrel compared to aspirin is always cost-effective
in the studied population.
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OBJECTIVES: To determine the attributes of future anti-
coagulation drug candidates necessary to demonstrate cost-
effectiveness versus traditional warfarin therapy in the 
prevention of stroke and major bleeds in Atrial Fibrillation
(“AF”) patients. METHODS: A decision-analytic model was
constructed to simulate the population of individuals using war-
farin therapy versus a proxy (future) anticoagulation drug in
patients with AF. Exposure period, dosage and base case proba-
bilities for major bleeds and hepatotoxity were based on the war-
farin raw data from the Sportif III and V trials. The beneﬁts
associated with using warfarin therapy versus a proxy future
drug in patients with AF were quantiﬁed using the quality-
adjusted life year (QALY) framework. Univariate and multivari-
ate probabilistic sensitivity analyses using Bayesian second-order
Monte Carlo simulation were conducted. Hepatoxicity-related
risks were estimated pursuant to FDA’s usage of Hy’s Law.
RESULTS: The results of the base-case analysis demonstrate that
treatment with warfarin results in an expected cost $307 less
than treatment with a proxy future anticoagulant drug ($882.70
compared with $1189.90, respectively). The proxy drug proﬁle
is not cost effective (incremental cost-effectiveness ratio of
$960,000 per QALY) compared to warfarin. Warfarin dominates
treatment vs. the proxy drug with 84% probability. CONCLU-
SIONS: Recent new anticoagulant candidate drugs have not been
shown to be cost-effective compared to warfarin. To achieve
market acceptance, future anticoagulant drugs must be able to
demonstrate competitive cost, non-inferiority of stroke/major
bleed prevention and a superior safety proﬁle including reduc-
tion of hepatotoxicity risk.
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